January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
January 2026 in “Frontiers in Drug Discovery” Transforming skin disease treatment requires new strategies, better drug models, and patient-focused research.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
December 2024 in “Highlights in Science Engineering and Technology” Stem cells show promise for hair regrowth, but challenges remain.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
October 2023 in “International journal of biology, pharmacy and allied sciences” Personalized treatment plans combining natural and synthetic approaches are important for managing alopecia effectively.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
February 2021 in “Journal of pharmaceutical and biological sciences” No cure exists for alopecia areata, and treatments are personalized.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
January 2016 in “Springer eBooks” Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.
1 citations
,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
July 2025 in “Cell & Bioscience” Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
March 2021 in “Uludağ Üniversitesi Tıp Fakültesi dergisi” The review provided information on various treatments to stop hair thinning and increase hair density in people with common genetic hair loss.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
3 citations
,
September 2024 in “JAAD reviews.” Topical corticosteroids are recommended first for treating pediatric alopecia areata due to their safety and ease of use.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
2 citations
,
March 2022 in “Journal of Personalized Medicine” Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.